Plain-English translation of NCT05899465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a medication that helps control bleeding and inflammation, can help prevent melanoma from returning after surgery. Half of the participants will receive the medication (given as an injection before surgery, then as tablets for several days after), and the other half will receive a placebo. Researchers want to see if this treatment can reduce early melanoma recurrence and improve outcomes.
Melanoma is an aggressive skin cancer, and many patients experience recurrence even after surgery to remove the tumor and nearby lymph nodes. This medication is being studied because it may reduce harmful inflammation and bleeding during surgery, which researchers believe could lower the risk of cancer cells spreading or coming back.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the medication or a placebo before your scheduled melanoma surgery. You'll get a single injection 30 minutes before the operation, then take tablets by mouth at specific times after surgery for about 5 days. You'll have follow-up visits over several months so researchers can check for any side effects, healing complications, and whether your melanoma has returned. Blood and tissue samples may also be collected to help understand how the medication affects your body's healing and immune response.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Denmark